Press release
FlyPharma Europe, Vienna – 23-24 October 2024 conference
October 14, 2024Conference, Corporate, flypharma, pharmaceutical
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return to Office Park 4, Vienna …
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
October 3, 2024Research and Development Ferring Pharmaceuticals, Gastrointestinal tract, ulcerative colitis
1 October 2024 – Saint-Prex, Switzerland – Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world …
Vertex Highlights First Oral Presentation of Phase 3 Clinical Dataof the Vanzacaftor Triple Combination and New Data on Long-Term Impact of TRIKAFTA at the North American CysticFibrosis Conference
September 30, 2024Vertex Pharma
Phase 3 data on investigational vanzacaftor triple combination demonstrates noninferiorityto TRIKAFTA® in ppFEV1 and further improvement of CFTR functionas measured …
Expanded possibilities for laboratory digitalization and connectivity: labforward merges with LabTwin
September 19, 2024Business Services, Research and Development AI, Corporate, LabTwin, laboratory
The two Berlin-based companies labforward and LabTwin, a subsidiary of the life science group Sartorius, are merging in order to …
Butterfly Network Expands its Next-Generation Butterfly iQ3™ to Europe
September 11, 2024Butterfly Network, medical imaging
Butterfly iQ3 is built on the next-generation Ultrasound-on-Chip™ technology featuring unparalleled image quality, new 3D imaging capabilities, and a smaller, …
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence in Lysosomal Storage Disorders
September 9, 2024Research and Development Rare Diseases
9 September 2024, –London, UK –Applications for the independently assessed, expert-led Research Grant Initiative, Find For Rare, are open from …
Amferia closes €1,2 million investment to combat resistant bacterial infections
September 3, 2024Research and Development Amferia, Chalmers Ventures, Dressings, hosiery & appliances, Hospital Management, Immunology, antimicrobial, investment, peptides
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. …
New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
Kerato Ltd Partners with University of Montreal to develop novel treatment for corneal damage
August 14, 2024Research and Development Kerato, Opthalmology, University of Montreal, corenas
BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce …
Pharma services boom in China as CPHI & PMEC China posts record attendance
August 8, 2024Conferencing, Events & Incentives, Public Relations, Sales and Marketing CPHI China, PMEC China, pharma
Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
August 6, 2024Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …
Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception
August 5, 2024Research and Development Contraception, UK, contraception, license extension
Gedeon Richter UK Ltd. (“Richter”) today announced that the Medicines Health Regulatory Authority (MHRA) has authorised an extension to the …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 5, 2024Research and Development GSK, Oncology, Reproductive health, endometrial cancer
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
August 1, 2024Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
